Detail akcie Evolus Rg online

Business Summary: Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Evolus Inc revenues increased 10% to $206.9M. Net loss increased 19% to $51.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 15% to $36.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.71 to -$0.81.